Anzeige
Mehr »
Login
Montag, 20.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 924471 | ISIN: US8771631053 | Ticker-Symbol:
NASDAQ
17.01.25
21:27 Uhr
33,700 US-Dollar
-0,410
-1,20 %
Branche
Maschinenbau
Aktienmarkt
Sonstige
1-Jahres-Chart
TAYLOR DEVICES INC Chart 1 Jahr
5-Tage-Chart
TAYLOR DEVICES INC 5-Tage-Chart
PR Newswire
322 Leser
Artikel bewerten:
(1)

Taylor Devices, Inc.: Taylor Devices Announces Third Quarter And Nine-month Results Including Record High Sales And Earnings

Finanznachrichten News

NORTH TONAWANDA, N.Y., March 28, 2024 /PRNewswire/ -- Taylor Devices, Inc. (NASDAQ SmallCap: "TAYD") announced today that it had 3rd quarter sales of $12,254,093, up 24% from last year's 3rd quarter sales of $9,891,272 while sales for the 1st nine months were $32,517,596, up 10% from last year's 1st nine-month sales of $29,479,337.

Net earnings for the 3rd quarter were $2,696,921, up significantly from last year's 3rd quarter net earnings of $1,658,887 with net earnings for the 1st nine months finishing at $6,526,132, also up significantly from last year's net earnings for the 1st nine months of $4,220,766.

"Our FY24 3rd quarter and 1st nine-month sales finished significantly better than last year's levels respectively with the benefit of our market diversity demonstrated by increased sales to our Aerospace/Defense product group customers more than offsetting a decrease in sales to our Structural product group customers," stated Tim Sopko, CEO. He continued, "Additionally, these sales levels establish new company highs for sales in a quarter as well as the 1st nine months of a fiscal year." He further commented, "Similarly, net earnings for the 3rd quarter and 1st nine months are also significantly improved over last year's levels both in total dollars as well as a percentage of sales; 63% better for the quarter and 55% better for the 1st nine months, while also establishing new company highs for net earnings in a quarter as well as the 1st nine months of a fiscal year." He further commented, "We continue to reap the benefits of our team's disciplined adherence to our growth strategies as well as their excellent work on continuous improvements implemented over the past several years across all functions in our business." He concluded, "As we enter the 4th and final quarter of our FY24, we will continue to focus on our growth strategies supported by our continued investments in our team, technologies (R&D) and facilities which we expect will continue to support our profitable growth going forward."

The company's firm order backlog was $30,200,000 at the end of this February as compared to $27,800,000 at the end of February last year.

Taylor Devices, Inc. is a 68-year-old company engaged in the design, development, manufacture and marketing of shock absorption, rate control and energy storage devices for use in various types of vehicles, machinery, equipment and structures. The company continues to target growth in the domestic Aerospace and Defense market as well as global Structural Construction and Industrial markets.

3 rd Quarter (3 months ended 02/29/24 & 02/28/23)

F/Y 24


F/Y 23

Sales

$ 12,254,093


$ 9,891,272

Net Earnings

$ 2,696,921


$ 1,658,887

Earnings per Share

$ 0.82


$ 0.47

Shares Outstanding

3,302,497


3,505,849





1 st Nine months (ended 02/29/24 & 02/28/23)

F/Y 24


F/Y 23

Sales

$ 32,517,596


$ 29,479,337

Net Earnings

$ 6,526,132


$ 4,220,766

Earnings per Share

$ 1.91


$ 1.20

Shares Outstanding

3,411,703


3,502,982

Taylor's website can be visited at: www.taylordevices.com; with company newsletters and other pertinent information at www.taylordevices.com/investors.

Taylor Devices, Inc.



Contact:

Artie Regan


Regan & Associates, Inc.


(212) 587-3005 (phone)


(212) 587-3006 (fax)


[email protected]

SOURCE Taylor Devices, Inc.

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.